Investor Relations
TSXV:NRX | OTCQB:NRXBF | FSE: J90
Transforming Regenerative Medicine
Nurexone's mission is to pioneer regenerative medicine targeting nerve and tissue regeneration for recovery from Spinal Cord Injuries (SCI), Traumatic Brain Injury (TBI) and a wide variety of indications.
We're developing ExoPTEN, a first nanodrug aimed at motor, sensory and functional recovery form acute spinal cord injury
Get Investor Updates
Financials & Filings
2025
2024
2023
2022
Latest News
February 1, 2026
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
December 19, 2025
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
December 12, 2025
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
Presentations
Latest
Presentation
One Pager
Optic Nerve
One Pager
Exo-Top
One Pager
ISEV TECH
Fact Sheet
AAEV
Analyst Reports
2025
December 1, 2025
NRXBF: Tremendous Progress Made in Groundbreaking Treatment
By Zacks Small Cap Research
September 9, 2025
NRXBF: US Patent Awarded for Cell Technology
By Zacks Small Cap Research
August 11, 2025
NRXBF: Company Treatment Outperforms Industry Standard
By Zacks Small Cap Research
July 8, 2025
NRXBF: Test Results Show Spinal Injury Recovery
By Zacks Small Cap Research
May 27, 2025
NRXBF: Company Remains Disciplined Amid Progress
By Zacks Small Cap Research
April 10, 2025
NRXBF: Critical Year Starts with Company in Good Shape
By Zacks Small Cap Research
March 17, 2025
NRXBF: Tests Confirm Potential for Spinal Cord Injury Recovery
By Zacks Small Cap Research
2024
FRC provides fee-based coverage
December 11, 2024
Initiating Coverage: A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment
By Fundamental Research Corp.
October 2, 2024
Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries
By Zacks Small Cap Research
Events
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|